<DOC>
	<DOCNO>NCT00994721</DOCNO>
	<brief_summary>Study Design： Adjuvant gemcitabine therapy show improve recurrence-free survival pancreatic cancer underwent curative intent resection . This study evaluate whether combine concurrent chemo-radiotherapy improve recurrence-free survival benefit adjuvant gemcitabine chemotherapy pancreatic cancer underwent curative resection . Research Objective Study End Points 1 . Primary endpoint： The primary end point disease free survival . 2 . Secondary endpoints： The secondary end point evaluate overall survival , local distant recurrence rate , impact quality life adjuvant gemcitabine without CCRT curatively resect pancreatic cancer . Furthermore , clinical , pathological molecular prognostic factor curatively resect pancreatic cancer evaluate .</brief_summary>
	<brief_title>A Phase III Study Pancreatic Cancer</brief_title>
	<detailed_description>Treatment plan Randomization scheme : ： Patients randomize stratification accord pathology report section margin , tumor size , lymph node metastasis : Patients randomize Arm 1 receive adjuvant chemotherapy start within 4-8 week surgery , administer D1 , D8 D15 every 4 week 6 cycle ( 6 month ) . Patients allocate Arm 2 receive sandwich treatment , comprise adjuvant chemotherapy within 4-8 week surgery 3 cycle ( 3 month ) , follow CCRT ( start 4-6 week last dose 3rd cycle chemotherapy ) another 3 cycle gemcitabine monotherapy . Statistical Consideration : We anticipate 2-year disease free survival increase 25 % 40 % incorporation CCRT adjuvant treatment post-operative pancreatic adenocarcinoma . With significant level 0.05 , 107 patient require treatment arm reach 80 % statistical power . Since drop rate approximately 10 % , 265 patient enrolled ensure 214 ( 107x2 ) eligible patient study . We anticipate recruit roughly 67 patient per year , therefore , patient recruitment complete 4 year . Randomization scheme : Histo-/cyto-logically confirm macroscopic complete resect pancreatic adenocarcinoma 1 . The primary end-point disease free survival . 2 . The secondary end-points overall survival ; local distant control rate , quality life . 3 . The clinical molecular prognostic factor overall survival . - Radiation field encompass initial main tumor pancreas safe margin 1cm . Lymph node region initially involved tumor confirm excision include clinical target volume . Elective radiation uninvolved lymph node give .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>A.Eligibility Criteria 1 . Patients pancreatic cancer curative intent resection . 2 . The histology resect tumor adenocarcinoma . 3 . Age 2075 year . 4 . ECOG performance scale 01 . 5 . Patients must normal organ marrow function define . 6 . The effect study agent develop human fetus recommend therapeutic dose unknown . 7. sign write informed consent . 8 . Registered within 6 week surgery . 9 . Preoperative abdominal CT MRI contrast enhancement . B.Exclusion Criteria 1 . Patients gross residual , macroscopic positive resection margin distant metastasis . 2 . Patients may receive investigational agent . 3 . Patients prior chemotherapy radiotherapy eligible . 4 . History allergic reaction . 5 . Patients noncurable second primary malignancy . 6 . Uncontrolled intercurrent illness include . 7 . Pregnant woman . 8. receive immunosuppressive therapy、anticoagulants .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Pancreatic Cancer</keyword>
</DOC>